Preparation of Novel 4′-Spirocyclopropyl Nucleoside Analogues

Jonas Verhoeven; Hanchu Kong; Yongbin Zhao; Wenbin Wang; Vineet Pande; Marta Brambilla; Kristof Van Hecke; Lieven Meerpoel; Jan Willem Thuring; Guido Verniest

doi:10.1055/a-1386-7194

Synlett, Table of Contents

Synlett 2021; 32(09): 892-896
DOI: 10.1055/a-1386-7194

letter

Preparation of Novel 4′-Spirocyclopropyl Nucleoside Analogues

Jonas Verhoeven ∗

^aResearch Group of Organic Chemistry (ORGC), Department of Chemistry and Department of Bio-engineering Sciences, Faculty of Science and Bio-engineering Sciences, Vrije Universiteit Brussel (VUB), Pleinlaan 2, 1050 Brussels, Belgium

^cJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium

,

Hanchu Kong

^bDepartment of Synthetic Chemistry, Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. of China

,

Yongbin Zhao

^bDepartment of Synthetic Chemistry, Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. of China

,

Wenbin Wang

^bDepartment of Synthetic Chemistry, Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. of China

,

Vineet Pande

^cJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium

,

Marta Brambilla

^cJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium

,

Kristof Van Hecke

^dXStruct, Department of Chemistry, Ghent University, Krijgslaan 281-S3, 9000 Ghent, Belgium

,

Lieven Meerpoel

^cJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium

,

Jan Willem Thuring

^cJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium

,

Guido Verniest

^aResearch Group of Organic Chemistry (ORGC), Department of Chemistry and Department of Bio-engineering Sciences, Faculty of Science and Bio-engineering Sciences, Vrije Universiteit Brussel (VUB), Pleinlaan 2, 1050 Brussels, Belgium

^cJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium

› Author Affiliations

Abstract

All articles of this category

Abstract

The stereoselective preparation of a novel 4′-spirocyclopropyl nucleoside analogue has been developed by using a semibenzilic Favorskii rearrangement of a 4′-(2-chloro-3-oxocyclobutyl)spirofuranose as a key step. These chiral spirocyclic intermediates, readily obtained on a multigram scale from chiral-pool starting materials, were shown to be highly suitable precursors for achieving full stereoselectivity in the reduction–ring contraction sequence. The downstream introduction of a nucleobase through Vorbrüggen glycosylation successfully resulted in the formation of the corresponding novel 4′-spirocyclic nucleoside analogue in a stereospecific manner.

Key words

cycloaddition - spiro compounds - rearrangement - glycosylation - nucleosides - Favorskii rearrangement

Full Text

References

References and Notes

1a Boriack-Sjodin PA, Swinger KK. Biochemistry 2016; 55: 1557
1b Bernstein BE, Meissner A, Lander ES. Cell 2007; 128: 669
1c Rodríguez-Paredes M, Esteller M. Nat. Med. 2011; 17: 330
1d Ahuja N, Sharma AR, Baylin SB. Annu. Rev. Med. 2016; 67: 73

2a Brehmer D, Wu T, Mannens G, Beke L, Vinken P, Gaffney D, Sun W, Pande V, Thuring J.-W, Millar H, Poggesi I, Somers I, Boeckx A, Parade M, Heerde E. v, Nys T, Yanovich C, Herkert B, Verhulst T, Jardin MD, Meerpoel L, Moy C, Diels G, Viellevoye M, Schepens W, Poncelet A, Linders JT, Lawson EC, Edwards JP, Chetty D, Laquerre S, Lorenzi MV. Cancer Res. 2017; 77: DTT02-04
2b Wu T, Brehmer D, Beke L, Boeckx A, Diels GS. M, Gilissen RA. H. J, Lawson EC, Pande V, Parade MC. B. C, Schepens WB. G, Thuring JW. J. F, Viellevoye M, Sun W, Meerpoel L. WO 2016070097, 2016
2c Wu T, Millar H, Gaffney D, Beke L, Mannens G, Vinken P, Sommers I, Thuring J.-W, Sun W, Moy C, Pande V, Zhou J, Haddish-Berhane N, Salvati M, Laquerre S, Lorenzi MV, Brehmer D. In Proceedings of the American Association for Cancer Research Annual Meeting 2018, Chicago, April 14−18, 2018, Vol.78 (Suppl. 13). American Association of Cancer Research; Philadelphia: 2018.

3 Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, Krivtsov A, Armstrong SA, DiMartino J, Hedrick E, Löwenberg B, Tallman MS. Blood 2018; 131: 2661

4a Maougal M, Escudier J.-M, Len C, Dubreuil D, Lebreton J. In Chemical Synthesis of Nucleoside Analogues . Merino P. Wiley; Hoboken: 2013
4b Morquez VE. In Modified Nucleosides in Biochemistry, Biotechnology and Medicine. Herdewijn P. Wiley-VCH; Weinheim: 2008. 305

5a Verhoeven J, Verniest GA. F, Thuring JW. J. F, Wu T, Pande V, Meerpoel L, Brehmer D, Sun W, Denmark SE. WO 2019110734, 2019
5b Verhoeven J, De Vleeschouwer F, Kong H, Van Hecke K, Pande V, Sun W, Vos A, Wu T, Meerpoel L, Thuring JW, Verniest G. Chem. Eur. J. 2019; 25: 15419

6a Boyer SH, Ugarkar BG, Solbach J, Kopcho J, Matelich MC. Ollis K, Gomez-Galeno JE, Mendonca R, Tsuchiya M, Nagahisa A, Nakane M, Wiesner JB, Erion MD. J. Med. Chem. 2005; 48: 6430
6b Köllmann C, Wiechert SM, Jones PG, Pietschmann T, Werz DB. Org. Lett. 2019; 21: 6966
6c Nowak I, Robins MJ. J. Org. Chem. 2006; 71: 8876
6d Lemaire S, Diène C, Gavryushin A, Du Jourdin XM, Paolini L, Jusseau X, Knochel P, Farina V. J. Org. Chem. 2019; 84: 4910
6e Xu W, Abboud KA, Ghiviriga I, Dolbier WR. Jr, Rapp M, Wnuk SF. Org. Lett. 2006; 8: 5549
6f Jonckers TH. M, Lin T.-I, Buyck C, Lachau-Durand S, Vandyck K, Van Hoof S, Vandekerckhove LA. M, Hu L, Berke JM, Vijgen L, Dillen LL. A, Cummings MD, de Kock H, Nilsson M, Sund C, Rydegård C, Samuelsson B, Rosenquist Å, Fanning G, Van Emelen K, Simmen K, Raboisson P. J. Med. Chem. 2010; 53: 8150
6g Liu X, Xia X, Sun C, Lin C, Zhou Y, Hussain M, Tang F, Liu L, Li X, Zhang J. Nucleosides, Nucleotides Nucleic Acids 2016; 35: 479
6h Rapp M, Cai X, Xu W, Dolbier WR. Jr, Wnuk SF. J. Fluor. Chem. 2009; 130: 321

7a Brand C, Rauch G, Zanoni M, Dittrich B, Werz DB. J. Org. Chem. 2009; 74: 8779
7b Ramakrishna B, Sridhar PR. RSC Adv. 2015; 5: 8142

8 Belluš D, Ernst B. Angew. Chem. Int. Ed. 1988; 27: 797

9a Conia JM, Salaun JR. Acc. Chem. Res. 1972; 5: 33
9b Garin DL, Cammack KL. J. Chem. Soc., Chem. Commun. 1972; 333
9c Salaun J, Garnier B, Conia JM. Tetrahedron 1973; 29: 2895

10 Verniest G, Bombeke F, Kulinkovich OG, De Kimpe N. Tetrahedron Lett. 2002; 43: 599
11 The use of methanol as a solvent initially led to the partial (35%) formation of a ring-opened methyl ester byproduct (see Supporting Information); however, this competing side reaction could be avoided by employing THF as the reaction solvent.

12a Brook PR, Duke AJ. J. Chem. Soc. D. 1970; 652
12b Brook PR. Chem. Commun. 1968; 565

13 CCDC 2049503 contains the supplementary crystallographic data for compound 13. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures

14a McMurry JE, Bosch GK. Tetrahedron Lett. 1985; 26: 2167
14b McMurry JE, Bosch GK. J. Org. Chem. 1987; 52: 4885
14c Nakyama Y, Nagase M. J. Org. Chem. 1995; 60: 1878
14d Todd MA, Sabat M, Myers WH, Harman WD. J. Am. Chem. Soc. 2007; 129: 11010
14e Saitoh H, Sampei T, Kimura T, Kato Y, Ishida N, Satoh T. Tetrahedron Lett. 2012; 53: 3004
14f Stadler H. Helv. Chim. Acta 2015; 98: 1189

15 (1S,3a'S,6'R,6a'R)-2-Chloro-6'-methoxy-2',2'-dimethyldihydro-6'H-spiro[cyclobutane-1,4'-furo[3,4-d][1,3]dioxol]-3-one (14) Zn (3.06 g, 47.0 mmol, 7.00 equiv) was added to a solution of substrate 10a (2.00 g, 6.72 mmol, 1.00 equiv) in anhyd THF (30 mL), and the mixture was cooled to 0 °C. Glacial HOAc (0.39 mL, 6.7 mmol, 1.00 equiv) was added, and the solution was warmed to rt and stirred for 30 min. The mixture was then filtered through a pad of Celite that was rinsed with EtOAc (200 mL). The filtrate was washed with aq NaHCO₃ (3 × 50 mL) and brine (2 × 50 mL) then dried (MgSO₄), filtered, and concentrated in vacuo to give a pale-yellow oil; yield: 1.77 g (quant); R_f = 0.33 (hexane–EtOAc, 4:1). ¹H NMR (500 MHz, CDCl₃): δ = 5.01 (s, 1 H), 4.98 (d, J = 5.8 Hz, 1 H), 4.83 (dd, J = 4.1, 1.9 Hz, 1 H), 4.68 (d, J = 5.8 Hz, 1 H), 3.52 (dd, J = 18.7, 1.91 Hz, 1 H), 3.42 (dd, J = 18.8, 4.16 Hz, 1 H), 3.41 (s, 3 H), 1.44 (s, 3 H), 1.35 (s, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ = 197.1, 113.0, 108.7, 85.3, 81.9, 79.5, 69.7, 55.3, 49.9, 26.3, 25.2. [(1R,2S,3a'S,6'R,6a'R)-6'-Methoxy-2',2'-dimethyldihydro-3a'H-spiro[cyclopropane-1,4'-furo[3,4-d][1,3]dioxol]-2-yl]methanol (15) Product 14 (27.0 g, 103 mmol, 1.00 equiv) was dissolved in anhyd THF (270 mL) and cooled to 0 °C. NaBH₄ (19.6 g, 515 mmol, 5.00 equiv) was added in a portionwise manner, and the mixture was stirred at rt for 1 h. 1 M aq NaOH (1080 mL) was added, and stirring was continued for 24 h at 50 °C. The product was extracted with EtOAc (3 × 500 mL) and the combined organic layers were dried (MgSO₄), filtered, and concentrated in vacuo. The residue was purified by column chromatography [silica gel, heptane–EtOAc (gradient 99:1 to 1:1)]. The fractions containing the product were collected and the solvent was evaporated to afford a colorless oil; yield: 14 g (59%, 60.8 mmol). ¹H NMR (300 MHz, CDCl₃): δ = 4.94 (s, 1 H), 4.68 (d, J = 5.9 Hz, 1 H), 4.60 (d, J = 5.9 Hz, 1 H), 3.93 (dd, J = 11.6, 5.8 Hz, 1 H), 3.34 (s, 3 H), 3.24 (dd, J = 11.6, 9.5 Hz, 1 H), 1.51 (s, 3 H), 1.46–1.39 (m, 1 H), 1.35 (s, 3 H), 1.25 (dd, J = 10.0, 6.9 Hz, 1 H), 0.81 (t, J = 6.9 Hz, 1 H). ¹³C NMR (125 MHz, CDCl₃): δ = 112.5, 107.5, 85.3, 79.9, 69.2, 62.8, 55.0, 26.3, 26.2, 25.3, 9.8. GC/MS (ESI+): m/z [M – CH₃O]⁺ calcd for C₁₀H₁₅O₄: 199.10; found: 199.09: T _r = 6.80 min. (1S,3R,5R,6R,7S)-5-(6-Amino-9H-purin-9-yl)-1-(hydroxymethyl)-4-oxaspiro[2.4]heptane-6,7-diol (17) 6-Chloropurine (3.50 g, 22.6 mmol, 1.10 equiv) was dissolved in MeCN (62.4 mL), and N,O-bis(trimethylsilyl)acetamide (4.19 g, 20.6 mmol, 1.00 equiv) was added dropwise. The mixture was heated to 80 °C for 17 h, then cooled to r.t. A solution of diacetate 16 (7.80 g, 20.6 mmol, 1.00 equiv) in MeCN (54.6 mL) was added, followed by TMSOTf (5.49 g, 24.7 mmol, 1.20 equiv), and the mixture was heated to 80 °C for 2 h then cooled to r.t. The resulting mixture was extracted with EtOAc (×2) and sat. aq NaHCO₃, and the combined organic layers were washed with brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. The residue was purified column chromatography [silica gel, CH₂Cl₂–MeOH (gradient 99:1 to 30:1)]. The fractions containing the product were collected, and the solvent was evaporated. The residue (8.0 g, 16 mmol) was dissolved in 1,4-dioxane (80 mL), and 25% aq NH₃ (20 mL) was added. The mixture was heated to 80 °C for 17 h then cooled to r.t. The solvent was removed in vacuo, and the product was dissolved in MeOH (80 mL). NaOMe (0.74 g, 14 mmol, 1.00 equiv) was added, and the mixture was stirred at r.t. for 30 min. It was then stirred with H⁺ exchange resin to pH 7. The mixture was filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography [silica gel, CH₂Cl₂–MeOH (gradient 99:1 to 90:10)]. Fractions containing the product were collected, and the solvent was evaporated to give a white solid; yield: 4.20 g [70% (2 steps), 14.3 mmol]. ¹H NMR (400 MHz, CD₃OD): δ = 8.37 (s, 1 H), 8.21 (s, 1 H), 6.08 (d, J = 5.9 Hz, 1 H), 5.08 (dd, J = 5.9, 5.1 Hz, 1 H), 4.25 (d, J = 5.1 Hz, 1 H), 3.88 (dd, J = 11.7, 5.9 Hz, 1 H), 3.26 (dd, J = 11.4, 9.7 Hz, 1 H), 1.46–1.60 (m, 1 H), 1.05 (dd, J = 10.3, 6.6 Hz, 1 H), 0.89 (t, J = 6.8 Hz, 1 H). ¹³C NMR (75 MHz, CD₃OD): δ = 157.5, 154.0, 150.7, 141.6, 120.6, 89.3, 77.3, 72.9, 72.3, 63.0, 25.9, 12.1. LC-MS (ESI+): m/z [M + H]⁺ calcd for C₁₂H₁₆N₅O₄: 294.11; found: 294.12; T _r = 0.48 min. HRMS (ESI+): m/z [M + H]⁺ calcd for C₁₂H₁₆N₅O₄: 294.1189; found: 294.1195.
16 Umbreen S, Linker T. Chem. Eur. J. 2015; 21: 7340

Supplementary Material

Supporting Information